春興精工(002547.SZ):擬通過債轉股方式對金寨春興增資
格隆匯2月27日丨春興精工(002547.SZ)公佈,公司持有金寨春興精工有限公司(簡稱“金寨春興”)100%股權,其中:公司直接持股98%,通過全資子公司蘇州春興投資有限公司(簡稱“春興投資”)間接持股2%。鑑於金寨春興的經營所需,爲合理優化其資產負債結構,支持其新能源汽車零部件產業的發展,公司與春興投資擬按持股比例等比例對其進行增資,其中:公司通過債轉股方式對其增資1.1564億元,前述債權係指公司對金寨春興的借款;春興投資通過現金方式對其增資236萬。增資完成後,金寨春興的註冊資本由13,200萬元增加至25,000萬元,本公司仍持有其100%股權,公司合併報表範圍不會發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.